Prior Authorization Required: Additional Information:
|
|
- Gerald Flowers
- 6 years ago
- Views:
Transcription
1 Genetic Testing for Somatic Tumor Markers MP9486 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below No A first-degree relative is defined as an individual s parents, full siblings, and children. A second-degree relative is defined as an individual s grandparents, grandchildren, aunts, uncles, nephews, nieces and half-siblings. A third-degree relative is defined as first cousins, great-aunts, great-uncles, great-grandchildren, or great-grandparents. Medicare Policy: BadgerCare Plus Policy: Prior authorization is dependent on the member s Medicare coverage. Prior authorization is not required for Medicare Cost (Dean Care Gold) and Medicare Supplement (Select) when this service is provided by participating providers. Prior authorization is required if a member has Medicare primary and Dean Health Plan secondary coverage. This policy is not applicable to our Medicare Replacement product (Dean Advantage). Dean Health Plan covers when BadgerCare Plus also covers the benefit. Dean Health Plan Medical Policy: 1.0 Individual tumor biomarker or gene expression classifier tests are considered medically necessary when ALL of the following criteria are met: 1.1 The individual is a candidate for a targeted therapy associated with a specific tumor biomarker or disease site; and 1.2 Results of testing will directly impact clinical decision making; and 1.3 The testing method is considered to be scientifically valid to identify the specific tumor biomarker; and 1.4 Either of the following: Identification of the specific gene or biomarker is required in order to initiate a related therapy and the therapy has been validated by the National Genetic Testing for Somatic Tumor Markers 1 of 11
2 Comprehensive Cancer Network (NCCN Guidelines ) as a category 1, 2A, or 2B recommendation for the individual s tumor type or disease site; or Identification of the specific biomarker has been demonstrated in published peer-reviewed literature to improve diagnosis, management or clinical outcomes for the individual s condition being addressed. 2.0 Multi-gene panels to direct proven therapy or management changes for hematologyoncology indications when all of the following criteria are met: 2.1 Sequential testing of individual genes or biomarkers is not practical (i.e., limited tissue available, urgent treatment decisions pending); and Identification of the genes or biomarkers on the panel has been demonstrated in published peer-reviewed literature to improve diagnosis, management, or clinical outcomes for the individual s tumor type or disease site; and The panel is targeted (e.g., < 10 genes) and limited to genes or biomarkers that are associated with the specific tumor type or disease site. 2.2 Use of multi-gene panel is validated by the NCCN as category 1, 2A, or 2B recommendation for the individual s tumor type or disease site. 3.0 Molecular testing for hematology-oncology indications and are considered experimental/investigational for the following situations: 3.1 There is insufficient evidence to support molecular testing for the specific tumor type or disease site and/or not recommended by NCCN guidelines; and 3.2 The requested gene(s) or biomarker(s) are correlated with a known therapy, but that therapy has not been validated for the specific tumor type or disease site. 4.0 Genetic testing for the following tumor types are medically necessary when an individual meets the testing criteria outline in the relevant NCCN guidelines. 4.1 Acute Lymphoblastic Leukemia BCR-ABL1 Fusion gene testing may be indicated when 1 or more of the following is present: Initial diagnosis of acute lymphoblastic leukemia, and need for risk stratification or treatment planning; or Philadelphia chromosome-positive acute lymphoblastic leukemia, and for assessment of minimal residual disease, as indicated by one or more of the following: Following completion of initial induction therapy; or Following complete remission; or Prior to and following stem cell transplant. Genetic Testing for Somatic Tumor Markers 2 of 11
3 4.1.3 Need for -ABL1 kinase domain mutation analysis in patient treated with tyrosine kinase inhibitors as indicated by: During the first-line tyrosine kinase inhibitor therapy, as indicated by 1 or more of the following: Suboptimal treatment response; or Treatment failure During second-line tyrosine kinase therapy, when there is hematologic or cytogenic failure. 4.2 Acute Promyelocytic Leukemia PML-RARA Fusion gene testing may be indicated for one or more of the following: Confirmation of diagnosis of acute promyelocytic leukemia; or Documentation of molecular remission following consolidation therapy; or Documentation of molecular remission following therapy for relapse. 4.3 Chronic Myelogenous Leukemia BCR-ALB1 Fusion gene testing may be indicated when 1 or more of the following are present: Confirmation of diagnosis of chronic myelogenous leukemia; or Need for BCR-ABL1 kinase domain mutation analysis in patient treated with tyrosine kinase inhibitors, as indicated by one or more of the following: At diagnosis for patient in advanced phase of disease (e.g., accelerated phase, blast phase); or During first-line tyrosine kinase inhibitor therapy as indicated by 1 or more of the following: Loss of major molecular response associated with increase in BCR-ABL1 transcript levels; or Suboptimal treatment response; or Treatment failure During second-line tyrosine kinase inhibitor therapy, when there is hematologic or cytogenetic failure Monitoring response to therapy. 5.0 Lynch Syndrome Colorectal Tumor Analysis tumor analysis is medically necessary for ANY of the following: 5.1 Tumor testing for the gene BRAF V600E and MLH1 promoter hypermethlation of an individual with colon cancer when IHC tumor screening identified a loss of MLH1 expression; or Genetic Testing for Somatic Tumor Markers 3 of 11
4 5.2 Microsatellite instability (MSI) testing of endometrial tumor tissue as an initial screen in an individual with colorectal and/or endometrial cancer or colorectal adenomas (when malignant tissue is not available) for ANY of the following indications: Individual with colorectal or endometrial cancer, or colorectal adenomas whose family meets EITHER of the following: Endometrial cancer < 50 years of age; or The Amsterdam II criteria are met, which includes at least three relatives with a Lynch syndrome related cancer and ALL of the following: Genetic Testing for Somatic Tumor Markers 4 of One must be a 1 st -degree relative of the other two; or At least two successive generations must be affected; or No history of FAP in the colorectal cancer cases (if any) The revised Bethesda guidelines are met which includes ONE of the following: Colorectal cancer diagnosed under age 50; or Presence of synchronous, metachronous colorectal, or other Lynch syndrome related cancer, regardless of age; or Colorectal cancer with the MSI-I histology diagnosed in an individual who is under age 60; or Colorectal cancer diagnosed with one or more 1 st degree relatives with a Lynch syndrome related cancer, with one or the cancers diagnosed under age 50; or Colorectal cancer diagnosed in two or more 1 st or 2 nd degree relatives with a Lynch syndrome related cancer, regardless of age. 6.0 The following Metastatic Colorectal Tumor tests are medically necessary for the diagnosis and management of metastatic colorectal tumors: 6.1 NRAS gene analysis; 6.2 KRAS targeted gene analysis; 6.3 BRAF V600E targeted mutation testing 7.0 The following Colon Cancer genetic tests are considered experimental/investigational: 7.1 Colon Cancer Oncotype DX 7.2 Colon Cancer Gene Expression Assay GeneFx Colon
5 7.3 Colon Cancer Gene Expression Assay ColoPrint 8.0 Melanoma (Cutaneous) Gene Expression Profiling is considered experimental/investigational. 9.0 Malignant Melanoma in Tumor genetic testing is considered medically necessary when EITHER of the following criteria are met: 9.1 BRAF V600E mutation (the cobas 4800 BRAF mutation test) for person who are considering ZELBORAF (vemurafenib) for the treatment of unresectable or metastatic melanoma; or 9.2 The THxID BRAF test for detecting mutation of the BRAF gene (V600E or V600K) in persons with unresectable or metastatic melanoma who are being considered for treatment with TALFINALAR (dabrafenib) or MEKINIST (trametinib) Myelodysplastic Syndrome genetic testing including TET2, DNMT3A, TP53, SF3B1, SRSF2, U2AF1, ZRSR2, ASXL1, RUNX1, EZH2, NRAS, CBL, JAK2, SETBP1, IDH1, IDH2, ETV6 is considered medically necessary when EITHER of the following criteria are met: 10.1 MDS will bone-marrow biopsy confirmed intermediate risk using the IPSS, the WPSS, or the IPSS-R classification methods; or 10.2 Patient was treated on a lower-risk scale but did not experience a response to treatment Glioblastoma MGMT (O(6)-methylguanine-DNA methyltransferase) gene mutation assay testing for predicting response to TEMODAR (temozolomid) in persons with glioblastoma is medically necessary Janus Kinase 2 (JAK2) mutation genetic testing is considered medically necessary for the following diagnoses: 12.1 Polycythemia Vera (PV) 12.2 Essential Thrombocythemia or Thrombocytosis (ET) 12.3 Primary Myelofibrosis 13.0 MPL and CALR exon 9 mutation analysis are considered medically necessary for the following diagnosis when JAK2 testing has been performed and was negative: 13.1 Essential Thrombocythemia or Thrombocytosis (ET) 13.2 Primary Myelofibrosis 14.0 Oncotype DX Breast Cancer Assay is medically necessary for breast cancer to assess the need for adjuvant chemotherapy in a woman when ALL of the following criteria are met: 14.1 Recently diagnosed stage 1 or stage 2 breast cancer; and 14.2 Estrogen receptor positive; and Genetic Testing for Somatic Tumor Markers 5 of 11
6 14.3 HER2-receptor negative; and 14.4 No evidence of distant metastasis; and 14.5 Either of the following criteria: Axillary-node status is negative (or any axillary-node micrometastasis is no greater than 2.0 millimeters) whether the woman is pre- or postmenopausal; or Up to three positive axillary nodes in a post-menopausal woman Prosigna Breast Cancer Assay (PAM50) is medically necessary for breast cancer to assess the need for adjuvant chemotherapy in a woman when ALL of the following criteria are met: 15.1 Recently diagnosed stage 1 or stage 2 breast cancer; and 15.2 Estrogen receptor positive; and 15.3 HER2-receptor negative; and 15.4 Postmenopausal; and 15.5 No evidence of distant metastasis; and 15.6 Axillary node status is negative (or any axillary-node micrometastasis is no greater than 2.0 mm) Non-Small Cell Lung Cancer (NSCLC) the following tests are medically necessary for the diagnosis and management of non-small cell lung adenocarcinoma: 16.1 EGFR targeted gene analysis 16.2 Anaplastic lymphoma kinase (ALK) fusion gene (e.g., the Vysis ALK Break Apart FISH Probe Kit) for persons who are considering XALKORI (crizotinib) or ZYKADIA (ceritinib) for the treatment of non-small cell lung cancer (NSCLC) KRAS targeted gene analysis 16.4 HER2 (ERBB2) targeted gene analysis 16.5 BRAF V600E targeted mutation testing 16.6 ROS1 gene rearrangements 16.7 RET gene rearrangements 16.8 MET amplification 17.0 Prostate Cancer Molecular tumor testing of confirmed prostate cancer is experimental/ investigational for the following: 17.1 MicroDNA Detection - Cancer 17.2 Oncotype DX Prostate Genetic Testing for Somatic Tumor Markers 6 of 11
7 17.3 Prostate Cancer Genetic Profiles 17.4 Prostate Cancer HOXB13, MMR, PTEN, and TMPRSS2 Fusion Genes 17.5 Decipher 17.6 Prolaris 18.0 Prostate Cancer screening and prognostic genetic tests, ConfirmDx and PCA3 Assay, are considered medically necessary for prostate cancer when results will impact management and BOTH of the following criteria are met: 18.1 PSA > 3.0 ng/ml; and 18.2 Previous benign prostate biopsy or focal high grade prostatic intraepithelial neoplasia (PIN) 18.3 All other prostate cancer screening and prognostic genetic tests are considered experimental and investigational and not covered Thyroid Nodule Gene Expression Testing (Afirma Thyroid FNA Analysis or Interpace ThyGenX Oncogene Panel) may be medically necessary when ALL of the following are present: 18.1 Age 21 years or older; and 18.2 Thyroid nodule, as indicated by ALL of the following: Atypia of undetermined significance; and Follicular lesion of undetermined significance; and Hurthle/follicular neoplasm suspected Tumor Analysis or Gene Expression Profiling for ANY of the following solid tumor type is considered experimental/investigational: 19.1 Anal carcinoma 19.2 Basal cell carcinoma 19.3 Bone cancer 19.4 Cancer of unknown origin/unknown primary 19.5 Cervical cancer 19.6 Head and neck cancer 19.7 Heptobiliary cancer 19.8 Malignant mesothelioma 19.9 Non-Hodgkin lymphoma Penile cancer Testicular cancer Genetic Testing for Somatic Tumor Markers 7 of 11
8 19.12 Tracheal cancer Esophageal cancer in certain situations Squamous cell carcinoma of the skin Renal/kidney cancer 20.0 Other Tumor Profile Testing is not covered for ANY the following: 20.1 Molecular testing for detection of or circulating tumor cells for any hematology/oncology indication because it is considered experimental/ investigational Topographic genotyping for an indication is not covered because it is considered experimental/investigational Multi-gene cell-free tumor DNA assays or molecular testing of circulating tumor cells for a hematology/oncology indications are considered experimental/investigational. CPT/HCPCS Codes Related to MP9486 * The list of codes (and their descriptors, if any) is provided for informational purposes only and may not be all inclusive or current. Listing of a code in this medical policy does not imply that the service described by the code is a covered or non-covered service. Benefit coverage for any service is determined by the member s policy of health coverage with Dean Health Plan. Inclusion of a code above does not imply any right to reimbursement or guarantee claim payment. Other medical policies may also apply BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; other breakpoint, qualitative or quantitative BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s) CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis) Genetic Testing for Somatic Tumor Markers 8 of 11
9 81235 EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q) JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.val617phe (V617F) variant KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13) KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146) MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme), methylation analysis Microsatellite instability analysis (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) of markers for mismatch repair deficiency (eg, BAT25, BAT26), includes comparison of neoplastic and normal tissue, if performed NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61) PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; common breakpoints (eg, intron 3 and intron 6), qualitative or quantitative PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (eg, promyelocytic leukemia) translocation analysis; single breakpoint (eg, intron 3, intron 6 or exon 6), qualitative or quantitative Molecular Pathology Procedure Level Molecular Pathology Procedure Level Molecular Pathology Procedure Level Molecular Pathology Procedure Level Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed Genetic Testing for Somatic Tumor Markers 9 of 11
10 81450 Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mrna expression levels, if performed Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed Unlisted molecular pathology procedure Oncology (breast), mrna, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score Oncology (colon), mrna, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffinembedded tissue, algorithm reported as a recurrence score Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result Oncology (tumor of unknown origin), mrna, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffinembedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious) 0008M S3854 Oncology (breast), mrna analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (FFPE) tissue, prognostic algorithm reported as a risk score Gene expression profiling panel for use in the management of breast cancer treatment Genetic Testing for Somatic Tumor Markers 10 of 11
11 Originated: Revised: Reviewed: Committee/Source Date(s) Medical Policy Committee/Quality and Care Management Division April 3, 2017 Medical Policy Committee/Quality and Care Management Division October 18, 2017 Medical Policy Committee/Quality and Care Management Division October 18, 2017 Published/Effective: 11/01/2017 Genetic Testing for Somatic Tumor Markers 11 of 11
Genetic Testing for Somatic Tumor Markers
Genetic Testing for Somatic Tumor Markers MP9486 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Genetic testing is covered for a
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationPrior Authorization. Additional Information:
Genetic Testing for Cowden Syndrome - PTEN Gene MP9488 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationPrior Authorization. Additional Information:
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationYes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationGenetic Testing for Lynch Syndrome
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post-test genetic counseling is
More informationMolecular Testing of Solid and Hematologic Tumors and Malignancies
Clinical Appropriateness Guidelines Molecular Testing of Solid and Hematologic Tumors and Malignancies EFFECTIVE MARCH 31, 2019 Appropriate.Safe.Affordable 2019 AIM Specialty Health 2066-0319 Table of
More informationGenetic Testing for Somatic Tumor Testing
Clinical Appropriateness Guidelines Genetic Testing for Somatic Tumor Testing EFFECTIVE DECEMBER 1, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2066-1217 Table of Contents Scope... 3 Appropriate
More informationMEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17
MEDICAL POLICY SUBJECT: MOLECULAR PANEL TESTING OF PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationMolecular Testing of Solid and Hematologic Tumors and Malignancies
Clinical Appropriateness Guidelines Molecular Testing of Solid and Hematologic Tumors and Malignancies EFFECTIVE OCTOBER 14, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2066-1017 Table of
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationDiagnostics for the early detection and prevention of colon cancer
Diagnostics for the early detection and prevention of colon cancer Cologuard Test Crosswalk Proposal July 14 th, 2014 Colorectal cancer: the second-leading U.S. cancer killer Annual U.S. cancer mortality
More informationLaboratory Service Report
Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-ih2xuglwpq.ashx Indication for Test DS CR Pathogenic utations Detected CR 1. JAK2: c.1849g>t;p.val617phe
More informationContractor Information. LCD Information
Local Coverage Determination (LCD): MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (L36044) Links in PDF documents are not guaranteed to work. To follow a web link, please use the
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationGenetic Testing for Pharmacogenetics
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below (1.0 and 3.0) Additional Information: None Prevea360 Health Plan
More informationDiagnostic test Suggested website label Description Hospitals available
Diagnostic test Suggested website label Description Hospitals available Abbott Molecular Inc, PATHVYSION HER-2 DNA Probe Kit (FISH) PathVysion kit A diagnostic tool used to determine whether a particular
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationContractor Information
Local Coverage Determination (LCD): MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (L36186) Links in PDF documents are not guaranteed to work. To follow a web link, please use the
More informationYes if indicated below. (4.0 TMPT does not require prior authorization)
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Prior Authorization Required: Additional Information: Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Yes if indicated
More informationMatthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory
Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &
More informationGenetic Testing Oncology
Genetic Testing Oncology Policy Number: Original Effective Date: MM.02.010 05/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2014 Section: Medicine Place(s) of Service:
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationIntroduction of an NGS gene panel into the Haemato-Oncology MPN service
Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing for BRCA1 and BRCA2 Genes MP9478 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic counseling
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationMEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Molecular Tumor Markers for Non-Small Cell Lung Cancer (NSCLC) MP-061-MD-DE Medical Management Provider Notice Date: 10/15/2018;
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More informationNext Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationLaboratory Service Report
Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationTumor Profiling, Gene Expression Assays and Molecular Diagnostic Testing for Hematology/Oncology Indications
Medical Coverage Policy Effective Date... 11/15/2017 Next Review Date... 11/15/2018 Coverage Policy Number... 0520 Tumor Profiling, Gene Expression Assays and Molecular Diagnostic Testing for Hematology/Oncology
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing f BRCA1 and BRCA2 Genes MP9478 Covered Service: Pri Authization Required: Additional Infmation: Yes when meets criteria below Yes--as shown below Pre and post-test genetic counseling is
More informationSchool of Pathology and Laboratory Medicine: Current and New Research Interests
School of Pathology and Laboratory Medicine: Current and New Research Interests W/Professor Wendy Erber Current Research Interests Viral immunology and immunogenetics Bone pathology and cell signalling
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Oncologic Genetic Testing Panels MP-074-MD-PA Medical Management Provider Notice Date: 11/15/2018 Issue Date: 12/15/2018 Effective
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES GENETIC CANCER SUSCEPTIBILITY PANELS USING NEXT GENERATION SEQUENCING The purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationCPT 2016 Code Changes
CPT 2016 Code Changes Code Changes - Pathology and Lab New CPT 2016 New Codes Code Description 80081 Obstetric panel (includes HIV testing) This panel must include the following: Blood count, complete
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationContractor Information. LCD Information
LCD for Biomarkers for Oncology (L35396) See also: A52986-Biomarkers for Oncology Contractor Name: Novitas Solutions, Inc. Contractor Number: 12502 Contractor Type: MAC B LCD ID Number: L35396 Status:
More informationmolecular oncology services
Molecular Oncology molecular oncology services ATIENTS.ANSWERS.RESULTS. www.aruplab.com/oncology MARCH 2018 Information in this brochure is current as of March 2018. All content is subject to change. lease
More informationPrecision Medicine and Molecular Testing.
Precision Medicine and Molecular Testing. David A. Sallman, MD Assistant Member Department of Malignant Hematology Moffitt Cancer Center david.sallman@moffitt.org Disclosures Research funding for Celgene
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Panel Testing of Cancers to Identify Targeted Therapies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_panel_testing_of_cancers_to_identify_targeted_therapies
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationCollaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st
More informationSelect analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie
Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationMOLECULAR ONCOLOGY TESTING FOR CANCER DIAGNOSIS, PROGNOSIS, AND TREATMENT DECISIONS
UnitedHealthcare Oxford Clinical Policy MOLECULAR ONCOLOGY TESTING FOR CANCER DIAGNOSIS, PROGNOSIS, AND TREATMENT DECISIONS Policy Number: LABORATORY 025.5 T2 Effective Date: July 1, 2018 Table of Contents
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationA Molecular Update for Cytopathology
A Molecular Update for Cytopathology Olga S. Chajewski, M.D. Assistant Professor Medical University of South Carolina Department of Pathology & Laboratory Medicine McKee Cytology Seminar April 21 st, 2018
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Grade Biomarkers in the Genomic Era Observations & Challenges
Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,
More information